4588.T JPX
Oncolys BioPharma Inc.
1W: -4.8%
1M: +28.6%
3M: +102.2%
YTD: +174.1%
1Y: +852.2%
3Y: +1024.1%
5Y: +267.8%
¥6,490.00 ($41.16)
+510.00 (+8.53%)
Weekly Expected Move ±14.7%
¥4216
¥5098
¥5980
¥6862
¥7744
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$29M
-9.0% ▼
5Y CAGR: -38.1%
Gross Profit
$28M
-9.8% ▼
5Y CAGR: -34.6%
Operating Income
-$2.0B
-20.4% ▼
Net Income
-$2.1B
-22.2% ▼
EPS (Diluted)
$-80.00
-3.7% ▼
EBITDA
-$2.0B
-22.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $642M | $976M | $63M | $31M | $29M |
| YoY Growth | +104.5% | +51.9% | -93.5% | -50.2% | -9.0% |
| Cost of Revenue | $444M | $638M | $32M | $815K | $242K |
| Gross Profit | $199M | $338M | $31M | $31M | $28M |
| Gross Margin | 30.9% | 34.7% | 48.6% | 100.0% | 99.2% |
| R&D Expenses | $825M | $947M | $1.4B | $1.1B | $1.5B |
| SG&A Expenses | $726M | $575M | $583M | $1.7B | $582M |
| Operating Expenses | $1.7B | $1.5B | $2.0B | $1.7B | $2.1B |
| Operating Income | -$1.5B | -$1.2B | -$1.9B | -$1.7B | -$2.0B |
| Operating Margin | -226.4% | -123.4% | -3061.6% | -5357.5% | -7090.5% |
| Interest Expense | $4M | $4M | $4M | $5M | $5M |
| Income Before Tax | -$1.6B | -$1.1B | -$1.9B | -$1.7B | -$2.1B |
| Tax Expense | $4M | $3M | $3M | $4M | $4M |
| Net Income | -$1.6B | -$1.1B | -$1.9B | -$1.7B | -$2.1B |
| Net Margin | -251.4% | -117.7% | -3075.1% | -5368.3% | -7209.6% |
| EPS (Diluted) | $-95.50 | $-66.31 | $-108.92 | $-77.17 | $-80.00 |
| EBITDA | -$1.6B | -$1.1B | -$1.9B | -$1.7B | -$2.0B |
| Shares Outstanding | 17M | 17M | 18M | 22M | 26M |